KYTX · Kyverna Therapeutics Inc
United States · RS rating 11 · As of 2026-10-14
| Price | 5.68 USD |
|---|---|
| 1-day change | -1.5% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 13 / 16 / 27 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 6 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +5.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +49.5% |
| Market cap (USD) | $541.7M |